GlassScriptPhysician profile
Nada Al-Hashimi
NPI 1538556246
$4,071.84
in general payments reported to CMS, 2019-2025
35 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $396 · 2021: $518 · 2022: $541 · 2023: $748 · 2024: $252 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,863.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,271.61 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $404.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $396.55 | 2019-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $320.58 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $246.16 | 2019-2020 | |
| Daiichi Sankyo INC. | $212.90 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $207.86 | 2020-2024 | Shingrix, Arexvy |
| Pfizer INC. | $111.42 | 2019-2024 | |
| Amarin Pharma, INC. | $107.48 | 2020-2021 | |
| Astellas Pharma US INC | $88.32 | 2025 | Veozah |
| Dynavax Technologies Corporation | $61.03 | 2023 | Heplisav-B |
| Exact Sciences Corporation | $54.97 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $46.47 | 2020 | |
| Boston Scientific Corporation | $45.76 | 2021 | |
| Ironwood Pharmaceuticals, INC | $44.02 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.37 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.59 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.29 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.83 | 2020 | |
| Janssen Pharmaceuticals, INC | $29.85 | 2019 | |
| Xeris Pharmaceuticals, INC. | $27.53 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $25.98 | 2024 | Percept PC Brainsense |
| Renalytix Ai, INC. | $25.00 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Shire North American Group INC | $23.04 | 2019 | |
| Shield Therapeutics INC | $20.00 | 2025 | |
| Esperion Therapeutics, INC. | $19.59 | 2021 | |
| Phadia US INC. | $19.03 | 2019 | |
| Genentech USA, INC. | $17.71 | 2019 | |
| Avion Pharmaceuticals | $17.00 | 2022 | |
| Currax Pharmaceuticals LLC | $15.70 | 2025 | Contrave |
| Althera Pharmaceuticals LLC | $15.53 | 2021 | |
| Teleflex LLC | $15.27 | 2021 | |
| Biogen, INC. | $15.24 | 2025 | Zurzuvae |
| Paratek Pharmaceuticals, INC. | $13.85 | 2023 | Nuzyra |
| Evofem Biosciences, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nada Al-Hashimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.